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High resolution CT scoreAbstract Introduction: Pathogenic sequences leading to the development of idiopathic pulmonary
ﬁbrosis (IPF) are unclear; but one theory is that, in a genetically susceptible host, there is a ‘‘trig-
gering agent or event inducing an inﬂammatory reaction in the lung that perpetuates itself and
causes parenchymal ﬁbrosis’’. One potential source for a self-perpetuating triggering event could
be a chronic viral infection. For this reason, evidence for an association between IPF and chronic
viral infection has been sought by many investigators for several different viruses, including HCV.
Objective: To estimate the prevalence of chronic hepatitis C virus infection in patients with idio-
pathic pulmonary ﬁbrosis via detection of HCV antibodies in selected patients in comparison to the
control group.
Patients and methods: In this study we evaluated 30 patients diagnosed with idiopathic pul-
monary ﬁbrosis according to diagnostic criteria of American Thoracic Society (ATS) in comparison
to 60 healthy control subjects. All enrolled subjects underwent a serologic test for HCV infection by
detecting hepatitis C surface antigen (HCVsAg) by a third-generation enzyme-linked immunosor-
bent assay (ELISA) test. All patients had undergone dyspnea severity assessment by the mMRC
score, routine laboratory testing including arterial blood gases (ABGs), pulmonary function testing
(PFTs), chest-X-ray, high resolution CT scan (HRCT), liver ultrasonography and bronchoscopy
(when needed).
Results: 9 IPF patients were positive for HCV (30%), while 17 control subjects were positive for
HCV (28.3%) (p= 0.869). In HCV positive IPF patients there were more severe dyspnea as
assessed by the mMRC score (p= 0.042*), lower FVC (p= 0.011*), SaO2% and PaO2 were signif-
icantly lower (p 6 0.001* for both parameters), and more severe HRCT scanning score
(p= 0.012*), in comparison to HCV negative IPF patients. There was signiﬁcant negativerculosis.
908 A.E.M. Rabea et al.correlation between the HRCT score and FVC (p= 0.011*) in HCV positive IPF patients, there
was signiﬁcant negative correlation between liver cirrhosis and PaO2 (p= 0.023
*), PaCO2
(p= 0.002*) in HCV positive IPF patients.
Conclusion: Despite the fact that we couldn’t conﬁrm the hypothesis that HCV can be a causa-
tive agent in the development of IPF, however, we have shown that HCV can be a predisposing
factor for the development of a more severe form of IPF. Therefore screening IPF patients for
the presence of underlying HCV infection can have important therapeutic and prognostic implica-
tions in those patients.
ª 2015 The Authors. Production and hosting by Elsevier B.V. on behalf of The Egyptian Society of Chest
Diseases and Tuberculosis. This is an open access article under the CC BY-NC-ND license (http://
creativecommons.org/licenses/by-nc-nd/4.0/).Introduction
IPF is deﬁned as a speciﬁc form of chronic, progressive ﬁbros-
ing interstitial pneumonia of unknown cause, occurring pri-
marily in older adults, limited to the lungs, and associated
with the histopathologic and/or radiologic pattern of UIP
(usual interstitial pneumonia) [1].
The deﬁnition of IPF requires the exclusion of other forms
of interstitial pneumonia including other idiopathic interstitial
pneumonias and ILD associated with environmental exposure,
medication, or systemic disease [1,2].
The incidence of IPF was estimated at 10.7 cases per
100,000 per year for men and 7.4 cases per 100,000 per year
for women in a population-based study from the county of
Bernalillo, New Mexico [3], the most recent estimated preva-
lence of IPF is 1.6–1.7/10,000 [4].
Hepatitis C virus (HCV), a ribonucleic acid (RNA) virus, is
now recognized as the major cause of non-A, non-B
transfusion-associated hepatitis. With improved diagnostic
techniques, HCV infection is increasingly identiﬁable and is
recognized as being associated with conditions other than hep-
atitis [5,6].
Chronic hepatitis C affects an estimated 170 million people
worldwide and causes approximately 350,000 deaths each year
[7]. The overall prevalence positive for antibody to HCV in
Egypt by released Egyptian Demographic Health Survey
[EDHS] 2008* was 14.7% [8]. The diverse HCV studies con-
ducted among different general population subgroups, regard-
less of design or methodology, consistently report a very high
HCV prevalence, as high as 41% in some studies [9].
Since HCV is well known to induce chronic inﬂammation
and ﬁbrosis in the liver, it was thought that HCV may play
a similar role in the lung and may be involved in the pathogen-
esis of pulmonary ﬁbrosis [10]. The pathogenic sequences lead-
ing to the development of IPF are unclear; but one theory is
that, in a genetically susceptible host, there is a ‘‘triggering
agent or event inducing an inﬂammatory reaction in the lung
that perpetuates itself and causes parenchymal ﬁbrosis’’ [11].
One potential source for a self-perpetuating triggering event
could be a chronic viral infection [12]. For this reason, evi-
dence for an association between IPF and chronic viral infec-
tion has been sought for several different viruses, including
HCV [13].
An association between HCV infection and IPF was ini-
tially supported by seroepidemiological data, which revealed
a higher prevalence of anti-HCV antibodies in patients with
IPF [14]. Onset of symptoms following a viral infection or
common cold in some patients suggests that development ofthe disease may be due to the injury related to the infection.
There is evidence that hepatitis C virus, Epstein–Barr virus
(EBV), and adenoviruses may be responsible for the ﬁbrosis
[15].
To our knowledge, there are only few studies that investi-
gated the association between IPF and HCV infection as a risk
factor, the present study aimed at investigating the prevalence
of chronic hepatitis c virus (HCV) infection in patients with
idiopathic pulmonary ﬁbrosis.Subjects and methods
Study design
A case control study was conducted in the Chest Diseases
Department, Faculty of Medicine, Alexandria University.
The study protocol was approved by the ethics committee of
the University and all study subjects were informed about
the study and their written consent was obtained.
Study subjects
The study protocol included 30 IPF patients, diagnosed
according to diagnostic criteria of American Thoracic
Society (ATS) with the following exclusion criteria: (1) patients
with other chronic pulmonary diseases. (2) Secondary causes
of IPF such as (congestive heart failure, suspected malignancy,
collagen tissue diseases, occupational lung diseases. (3)
Chronic liver diseases due to chronic hepatitis B virus infec-
tion, chronic alcoholism or autoimmune hepatitis. (4)
History of treatment with interferon in HCV positive patients.
Patients were compared with 60 age and sex matched con-
trol subjects
Laboratory investigations including
1. Complete liver proﬁle including: aspartate aminotrans-
ferase (AST), alanine aminotransferase (ALT) [16],
Bilirubin [16], Serum albumin [17], prothrombin time and
international normalized ratio (PT/ INR) [17].
2. Diagnosis of HCV infection by a third-generation enzyme-
linked immunosorbent assay (ELISA) test (Ortho
Diagnostic System, Raritan, New Jersey, USA) [18].
3. Investigations to exclude secondary causes of IPF e.g.
Collagenic proﬁle in the form of rheumatoid factor (RF),
LE cells, anti-nuclear antibody (ANA), and anti-double
strand DNA (anti-Ds. DNA) [19].
Table 1 Comparison between the studied groups according to
demographic data.
Cases (n= 30) Control (n= 60) p
No. % No. %
Sex
Male 13 43.3 25 41.7 0.880
Female 17 56.7 35 58.3
Age
Mean ± SD. 52.40 ± 8.30 49.62 ± 9.31 0.170
BMI
Mean ± SD. 30.37 ± 4.07 30.66 ± 3.64 0.738
Smoking index (n= 8) (n= 11)
Mean ± SD. 37.50 ± 16.78 24.82 ± 8.69 0.046*
p: p value for comparing between patients and control group.
* Statistically signiﬁcant at p 6 0.05.
Table 2 Comparison between the studied groups according to
prevalence of HCV infection.
Cases (n= 30) Control (n= 60) FEp
No. % No. %
HCV AB
ve 21 70.0 43 71.7 0.869
+ve 9 30.0 17 28.3
p: p value for comparing between patients and control group.
HCV infection in pulmonary ﬁbrosis patients 909Arterial blood gases (ABGs) [20]
ABG were done at rest on room air, by measuring the follow-
ing parameters: Arterial oxygen tension (PaO2), Arterial car-
bon dioxide tension (PaCO2), Oxygen percent saturation
(SaO2), and Level of serum bicarbonate (HCO3) in mEq/L.
Computerized pulmonary function tests [21]
The following lung function tests were performed: Forced vital
capacity (FVC), Forced expiratory volume after 1 s (FEV1),
FEV1/FVC, Peek expiratory ﬂow rate (PEF).
Plain chest X-rays and heart (P-A) view [22]
Radiological evidence of interstitial ﬁbrosis and pulmonary
hypertension were identiﬁed on the standard postero-anterior
view as follows:
Peripheral reticular opacities, most marked at the bases,
and often associated with honeycombing and lower lobe vol-
ume loss [22].
HRCT scanning
Multi detector computed tomography of the chest using a 16-
MDCT system (Aquilion 16, TOSHIBA medical systems).
Scans were performed using the following protocol; helical full
rotation 0.5 s, detector conﬁguration of 16 · 0.625, beam colli-
mation of 10 mm, helical thickness of 0.625 mm, pitch of 23
and a table speed of 23 mm/rotation. Images were acquired
at full inspiration from the lung apex to the base.
UIP is characterized on CT by the presence of reticular
opacities, often associated with traction bronchiectasis.
Honeycombing is common [23]. Ground glass attenuation is
common, but is usually less extensive than reticular abnormal-
ity [24]. Architectural distortion, reﬂecting lung ﬁbrosis, is
often prominent. Lobar volume loss is seen with more
advanced ﬁbrosis. The distribution of UIP on CT is character-
istically basal and peripheral, although often patchy. Different
CT ﬁndings were assessed and the results were scored by the
Semi-quantitative scoring method: Ooiet al. [25].
Bronchoscopic assessment [26]
Bronchoscopic assessment was done when the diagnosis was in
doubt, to exclude secondary causes, using Fiber-optic bron-
choscopy (KARL STORZ-Germany), all patients received
nasal oxygen (high-ﬂow) and midazolam to produce conscious
sedation, with recording of heart rate and oxygen saturation
by pulse oximetry. Broncho-alveolar lavage was done by instil-
lation of about 50–100 ml of normal saline to the middle lobe
then aspirated in a sterile container. BAL ﬂuid was sent for dif-
ferential cellular count and bacteriological analysis.
Liver ultrasonography [27]
For assessment of: (1) liver (shape, size, outline and texture
measurement), Hepatic veins and portal veins. Typical signs
of liver cirrhosis included homogenous echo texture and
irregular or nodular liver surface delineation. (2) Portalhypertension (dilated attenuated portal vein, coarse liver par-
enchyma, disturbed vascular architecture, collateral vessels,
and Presence of ascites or splenomegaly). (3) Abnormal liver
nodules like HCC (hepatocellular carcinoma).
Statistical analysis
Continuous variables were expressed as mean values with
Standard Deviation (SD) and the nominal variables as num-
bers and percentages. Analyses of the data involved testing
the differences in prevalence and comparison of the means.
Chi-square test (or Fisher’s exact test where appropriate) was
used for testing difference in the prevalence. Comparison of
spirometric measurements was performed by independent-
samples T-test. AP-values less than 0.05 were considered as
statistically signiﬁcant. Statistical analysis was performed
using the Statistical Package for the Social Sciences (SPSS)
version 11.0 for Windows.
Results
Characteristics of the studied groups
- Demographic characteristics were matched in both exam-
ined groups.(Table 1).
- A signiﬁcantly higher smoking index was found in IPF
cases in comparison to the control group at p= 0.046*.
Table 3 Patients’ characteristics according to the presence or
absence of HCV.
HCV p-value
ve (n= 21) +ve (n= 9)
No. % No. %
Dyspnea
II 9 42.9 0 0.0 0.042*
III 8 38.1 5 55.6




Mean ± SD. 40.52 ± 8.55 46.37 ± 7.61
PaO2 <0.001
*
Mean ± SD. 58.83 ± 9.97 42.33 ± 1.53
SaO2 <0.001
*
Mean ± SD. 89.28 ± 4.82 80.0 ± 1.79
PFT severity
FVC> 50% 11 52.4 0 0.0 0.011*
FVC< 50% 10 47.6 9 100.0
HRCT score
Mean ± SD. 20.90 ± 5.87 26.78 ± 4.52 0.012*
p: p value for comparing between patients and control group.
* Statistically signiﬁcant at p 6 0.05.
Table 4 Liver ultrasonography in IPF cases.
Cases
Liver cirrhosis No. %
No cirrhosis 21 70.0
Early cirrhosis 7 23.3
Moderate cirrhosis 2 6.7
Advanced cirrhosis 0 0.0
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- 9 cases were positive for HCV AB (30%) by the ELIZA
test, while in the control group 17 subjects were positive
(28.3%) by the ELIZA test at p= 0.869. No statistical dif-
ference was found in the prevalence of HCV infection
between IPF cases and the control group (Table 2).
Comparison between HCV positive and HCV negative IPF
cases: (Table 3)
1. Clinically: dyspnea as measured by mMRC score was more
severe in HCV positive IPF patients at p= 0.042.
2. Arterial blood gases: SaO2% and PaO2 were signiﬁcantly
lower in HCV positive IPF group at p=<0.001 for both
parameters.
3. Pulmonary function test: all HCV positive IPF patients
(100%) presented by FVC < 50%, while in HCV negative
IPF patients 10 cases (47.6%) presented by FVC < 50%, at
p= 0.011*.4. High resolution CT scanning score: HRCT score was more
severe in HCV positive IPF patients ranging from 21.0 to
36.0 with a mean ± SD of 26.78 ± 4.52, while In HCV
negative IPF patients it ranged from 13.0 to 37.0 with a
mean ± SD of 20.90 ± 5.87, the difference was statistically
signiﬁcant at p= 0.012*. Also there was signiﬁcant nega-
tive correlation between HRCT score and FVC at
p= 0.011*.
Bronchoscopic assessment
- Bronchoscopy was done to 7 selected patients to exclude
secondary causes of IPF. Alveolar Macrophages: ranging
from (20% to 50%), Neutrophils: ranging from (25% to
60%), Lymphocytes: ranging from (9% to 20%),
Eosinophils: ranging from (1% to 9%).
- Alveolar macrophages were the predominant cells in 4
patients, while neutrophils were the predominant cells in
3 patients. Neutrophilia was present in all patients with 3
patients presenting with (neutrophilia alone), 2 patients
(neutrophilia + eosinophilia), and 2 patients (neurophil-
ia + mild lymphocytosis).
Liver ultrasonography (Table 4)
- Liver cirrhosis: 21 cases (70%) presented with no cirrhosis,
7 cases (23.3%) with early cirrhosis, 2 cases (6.7%) with
moderate cirrhosis and no one with advanced cirrhosis.
- There was a signiﬁcant correlation between liver cirrhosis
and PaO2, PaCO2 at p= 0.023, p= 0.002 respectively.
Discussion
We studied 30 patients with IPF 13 males and 17 females; their
mean age was 52.4, compared with 60 healthy control subjects.
All IPF patients fulﬁlled American thoracic society standard
clinical criteria for the diagnosis of IPF.
In this study 9 (30%) of the IPF patients were positive for
HCV Abs by third generation ELIZA, while 17 (28.3%) con-
trol subjects were positive for HCV Abs, with no statistically
signiﬁcant difference in the prevalence of HCV infection
between IPF cases and control subjects.
The results of this study agree with IRVING et al. [28] who
studied stored sera from 62 patients in the UK with a clinical
diagnosis of IPF. This study utilized the ‘‘second generation’’
ELISA tests and RIBA for four HCV antigens, C100, 5-1-1,
C33 and C22. Irving et al. found equivocal evidence of HCV
antibody in only one patient, and conﬁrmatory reverse tran-
scriptase polymerase chain reaction (RT/PCR) was negative.
However the results of this study disagreed with Ueda et al.
[14] who ﬁrst suggested a relationship between IPF and HCV
infection by studying 66 Japanese patients with a clinical diag-
nosis of IPF, 9.464 control subjects who were healthy volun-
teers all over Japan using the ﬁrst generation enzyme-linked
immunosorbent assay (ELISA) tests for evidence of HCV
infection. 19 cases (28.8%) percent of the IPF patients studied
were found to be HCV antibody positive, while only 3.66% of
the control subjects were positive.
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these studies is that the serologic reactions reported from
Japan might be false positive, the screening ELIZA (ﬁrst gen-
eration) used in that report contains only the c100 antigen and
it is not clear whether the RIBA assay used contained c33c and
c22 antigens or whether any of the RIBA reactive sera gave
c33c or c22 bands. In order to detect HCV infection RIBA
must detect 5 of the peptides representing the core in HCV
genome (c22, c33, c100, c200, Ns3 and Ns4) and it has become
clear from extensive anti HCV screening of blood donors that
patients whose sera produce only C100 & 5-1-1 bands on
RIBA testing are unlikely to be truly infected with HCV.
Also raised IgG levels have also been shown to be a cause of
false positive anti C-100 results, a raised IgG level is found
in half of all patients with IPF. So there may be antibodies rec-
ognizing some epitope that mimics C100 antigen of HCV
involved in the pathogenesis of IPF [29,30].
Also this study’s results disagree with Arase et al. [31], who
studied 6150 HCV infected patients who were between 40 and
70 years old. Another 2050 patients with hepatitis B virus
(HBV) were selected as control. The mean observation period
was 8.0 ± 5.9 years in the HCV-group and 6.3 ± 5.5 years in
the HBV-group. He found that ﬁfteen patients in the HCV-
group developed IPF. On the other hand, none of the patients
developed IPF in the HBV-group. In the HCV-group, the
cumulative rates of IPF development were 0.3% at the 10th
year and 0.9% at the 20th year. The IPF development rate
in HCV-group was higher than that in HBV-group
(p= 0.021). May be this discrepancy between this study and
Arase et al. is due to difference in control groups selected
(his control group was HBV positive patients not healthy sub-
jects, his study was a prospective cohort study involving a lar-
ger number of patients while this study is a case control study.
The difﬁculties in interpretation of HCV and IPF are fur-
ther emphasized by Meliconi et al. [13], who studied Serum
samples obtained from 60 patients with IPF of mean age
61 years. Control groups included 130 patients with (chronic
obstructive lung disease 93, neuromuscular chest wall diseases
13, pulmonary vascular diseases 11, bronchiectasis 7, chronic
pleural diseases 4, tuberculosis 2) and 4614 blood donors.
The blood donors, as expected, had a lower rate (0.3%) of
HCV positivity than the general population. Eight of the 60
patients with IPF were positive for anti-HCV as detected by
ELISA (13.3%), a signiﬁcantly higher prevalence than that
obtained in the blood donor group (14/4614(0.3%),
p< 00001). Anti-HCV antibodies were found in eight of 130
patients (6.1%) with non interstitial lung disease, this preva-
lence is signiﬁcantly higher than that of blood donors
(p< 00001) but is not signiﬁcantly different from that of the
patients with IPF.
The study of Melconi is supporting the results of this study
as he found no statistical difference between the IPF group and
non interstitial pulmonary disease group as regards prevalence
of HCV infection and this means that HCV is an independent
factor in the development of IPF and not speciﬁcally related to
IPF.
However, the signiﬁcant higher prevalence found in the IPF
group in relation to the blood donor group in his study had
drawbacks and selection bias as regards risk factors, ﬁrst: mul-
tiple hospital admissions, is a risk factor for HCV exposure,
besides that; ﬁve of the eight anti-HCV positive IPF patients
had major risk factors (four had received multiple transfusionsand one was an intravenous drug abuser) and two had a his-
tory of surgical treatment, also the blood donor group subjects
do not represent the most appropriate control group as they
were younger and had a selection bias. People who volunteer
as blood donors are generally not at risk of hepatitis viruses.
The study of Meliconi et al. [13] clariﬁed the issue of diag-
nostic techniques, but emphasized that the baseline prevalence
of HCV infection in the population studied in every country
determines the results. In the USA and Western Europe, the
prevalence of HCV positivity is approximately 1%, in northern
Italy it is 3.4% and in some parts of Japan it is as high as 30%.
Also here in Egypt the prevalence of HCV reached in some
Egyptian studies 41%, [9] that’s why in this study we couldn’t
ﬁnd a relation between IPF and HCV as a causative agent.
Therefore, it is most likely that the relationship between IPF
and HCV is spurious and reﬂects the background of the preva-
lence of HCV in each country and the geographic difference in
etiopathogenesis of IPF.
However; HCV positive IPF patients presented with more
severe dyspnea and hypoxemia at (p 0.042*, p 0.001*) respec-
tively. HCV positive IPF cases presented with more severe dys-
pnea grade III and IV according to dyspnea scale mMRC [32],
and more hypoxemia with more impaired gas exchange, this is
explained by the more severe ﬁbrosis seen in HRCT of this
group.
Moreover; all HCV positive IPF cases presented with a
more severe restrictive pattern in PFTs compared with HCV
negative IPF cases, this also supports our ﬁnding of the more
extensive ﬁbrosis in HRCT of these patients. In addition, the
respiratory muscle fatigue that is already present in HCV
infected cases [33] can be another contributing factor.
Furthermore; statistically higher computed tomography
scores in HCV positive IPF patients compared with HCV neg-
ative IPF cases at p 0.012 by Semi-quantitative scoring:
Ooiet al. [25].
Positive HCV IPF cases showed higher HRCT scores
because they had more intense reticular ﬁbrosis and honey-
combing with more extension in lung lobes compared to
HCV negative group, may be by the same mechanism by which
the virus affects liver ﬁbrosis as HCV could potentially pro-
voke similar abnormalities in the lung, mainly because of its
lymphotropism, which can induce chronic immune activation
and inﬂammation [34].
Therefore, this worsening in the clinical and physiological
parameters as well as the radiological ﬁndings of HCV infected
IPF patients may reﬂect a more severe form of the disease in
those patients.
Also; there was a negative correlation between HRCT score
and FVC% in PFTs of HCV positive IPF cases at
(p= 0.011*). These results agree with Okutan et al. [35] in
(2004) who found negative correlation between HRCT and
FVC in patients with HCV infection with pulmonary intersti-
tial involvement. The latter ﬁnding reﬂects the increased lung
stiffness (reduced lung compliance) associated with increased
pulmonary ﬁbrosis, which leads to increased lung elastic recoil
[36].
The present study showed a negative correlation between
degree of liver cirrhosis with PaO2 in HCV positive IPF cases
at (p 0.023), and positive correlation with PaCO2 at
(p 0.002).This may be explained by the presence of intrapul-
monary vascular abnormalities which are a usual pathologic
ﬁnding in chronic liver disease that lead to limited diffusion
912 A.E.M. Rabea et al.of oxygen and ventilation perfusion mismatch that leads to
more hypoxia and dyspnea [37]. Also this may be due to
HCV lymphotropism, which can induce chronic immune acti-
vation and inﬂammation in the lung. The other possible mech-
anism is that antigens and antibodies from the bowel or other
organs enter portal circulation and are not separated sufﬁ-
ciently in patients with severe liver dysfunction. Immune com-
plexes that are formed by these antigens and antibodies enter
systemic circulation and accumulate in the glomeruli or lung,
so this deposition of Immune complexes in the lung can cause
more ﬁbrosis and further hypoxemia in HCV positive IPF
cases [38]. This further supports our previous ﬁndings that
the presence of HCV infection in IPF patients can cause a
more severe form of IPF.Conclusion
Despite the fact that we couldn’t conﬁrm the hypothesis that
HCV can be a causative agent in the development of IPF, how-
ever, we have shown that HCV can be a predisposing factor for
the development of a more severe form of IPF. Therefore,
screening IPF patients for the presence of underlying HCV
infection can have important therapeutic and prognostic impli-
cations in those patients.Conﬂict of interest
I declare that there is no conﬂict of interest that could
be perceived as prejudicing the impartiality of the research
reported.
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